Clinical trials: Non Proliferative Diabetic Retinopathy
Non Proliferative Diabetic Retinopathy(NPDR)
Clinical Study on Prognosis of Patients With Severe NPDR Undergoing Vitrectomy
To investigate the prognosis of retinal structure and function after vitrectomy in patients with severe non-proliferative diabetic retinopathy, to explore the feasibility of vitrectomy in patients with severe non-proliferative…
- Trial name
- NCT05852132
- Testing
- pars plana vitrectomy(PPV), Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP), Panretinal photocoagulation(PRP)
- Where
- China
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Fei Gao
Non-Proliferative Diabetic Retinopathy
Intravitreal and Intracameral DEX in NPDR
To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy
- Trial name
- NCT06951087
- Testing
- Dexamethasone sodium phosphate
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Affiliated Hospital of Nantong University
Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
The purpose of this study is to look at how effective, safe, and well tolerated Intravitreal Aflibercept Injection is in subjects with Central Retinal Vein Occlusion (CRVO) or Proliferative Diabetic Retinopathy (PDR).
- Trial name
- ANDROID (NCT01724554)
- Testing
- Intravitreal Aflibercept Injection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ophthalmic Consultants of Boston
Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy
In this phase IV, randomized, double-masked, sham-controlled study the investigators hope to determine the efficacy in peri-operative faricimab (Vabysmo) compared to sham in limiting complications from pars plana vitrectomy for…
- Trial name
- NCT06191094
- Testing
- Faricimab Injection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Colorado, Denver
Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Changes in Macular Thickness After Patterns Scan Laser
Laser photocoagulation has become the treatment of choice in PDR. Laser photocoagulation has become the treatment of choice in TMD.
- Trial name
- NCT00563628
- Testing
- Panretinal photocoagulation with PASCAL system
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy New Vessels on Disc
The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR)
Commonly know that one of the complications caused by Diabetes Mellitus (DM) is microangiopathy. Microangiopathy in the long term may lead to neuropathy of the corneal nerves.
- Conditions
- Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy New Vessels on Disc, Dry Eye Syndromes
- Trial name
- NCT04000789
- Testing
- Sodium Hyaluronate, Vitamin A, Vitamin E
- Volunteers
- 96 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy
Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy
The goal of this clinical trial is to evaluate whether remote ischemic conditioning (RIC) is a safe and effective treatment for non-proliferative diabetic retinopathy (NPDR) in adults aged 40-80 years with type 2 diabetes.
- Conditions
- Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy, Remote Ischemic Conditioning, Diabetes Mellitus, Type 2
- Trial name
- RIC-NPDR (NCT06713720)
- Testing
- Remote Ischemic Conditioning Device
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- Xuxiang Zhang, MD
Type2 Diabetes, Diabetic Retinopathy
Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy
This trial is planned to collect relevant clinical data to evaluate the prevention efficacy and safety of Tangningtongluo tablets on the non-proliferation period of diabetic retinopathy.
- Trial name
- NCT05007262
- Testing
- Tangningtongluo tablets, Calcium dobesilate capsules
- Where
- 13 sites in China
- Volunteers
- 240 people
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
Eye Diseases, Diabetes
Prophylactic PRP in Moderate NPDR
Diabetic retinopathy (DR) is a challenge to ophthalmic practice in communities with poor socioeconomic development. The COVID 19 pandemic has accentuated the challenge.
- Conditions
- Eye Diseases, Diabetes, Diabetic Retinopathy
- Trial name
- NCT05543564
- Testing
- PRP
- Where
- Egypt
- Volunteers
- 68 people
- Sponsor
- Assiut University
Nonproliferative Diabetic Retinopathy
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
Title of study: Effects of Ranibizumab to delay or regression non-proliferative diabetic retinopathy(NPDR) with DME assessed by microaneurysm changes: A pilot study Objectives Diabetic retinopathy (DR) is a major cause of visual…
- Trial name
- NCT02834663
- Testing
- Lucentis
- Volunteers
- 25 people
- Sponsor
- Wonkwang University Hospital
Diabetic Retinopathy
Diabetic Retinopathy Sulodexide Study
The aim of this phase 2 controlled placebo study is to assess the effectiveness of Sulodexide in the treatment of non proliferative (background) retinopathy in patients with Type 1 and Type 2 Diabetes Mellitus.
- Trial name
- DRESS (NCT01295775)
- Testing
- sulodexide
- Where
- South Korea
- Volunteers
- 127 people
- Sponsor
- Ajou University School of Medicine
Diabetic Non-proliferative Retinopathy, Type2 Diabetes
Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy
This study include 384 Participants with diabetic non-proliferative retinopathy Design Method: Randomized, double blind, placebo controlled and multicenter clinical study.
- Trial name
- NCT03025399
- Testing
- Tangwang prescription
- Volunteers
- 384 people
- Sponsor
- Fengmei Lian
Diabetic Retinopathy
Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2
This project aims to validate a predictive model of diabetic retinopathy progression to clinically significant macular edema (CSME) needing photocoagulation and/or vision loss.
- Trial name
- CPM (NCT00763802)
- Where
- Portugal
- Volunteers
- 400 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR).
- Trial name
- NCT06770933
- Testing
- VX-01
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Vantage Biosciences Ltd
Diabetic Retinopathy, Diabetic Macular Edema
Anti-VEGF Treatment for Prevention of PDR/DME
Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular…
- Trial name
- NCT02634333
- Testing
- Prompt aflibercept, Deferred laser, Deferred aflibercept
- Where
- 85 sites in United States, Canada
- Volunteers
- 399 people
- Sponsor
- Jaeb Center for Health Research
Non-proliferative Diabetic Retinopathy
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05695417
- Testing
- OTX-TKI
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ocular Therapeutix, Inc.
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period…
- Conditions
- Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema
- Trial name
- NCT06599684
- Testing
- INV-102
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Invirsa, Inc.
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopathy.
- Trial name
- NCT05393284
- Testing
- OPL-0401 Dose 1
- Where
- 25 sites in United States
- Volunteers
- 114 people
- Sponsor
- Valo Health, Inc.
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Trial name
- (PENGUIN) (NCT07354477)
- Testing
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Qlaris Bio, Inc.
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00131144
- Testing
- Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- Novartis